Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib for extensive-stage small cell lung cancer after etoposide/carboplatin response
ChiCTR1900028023Phase 4Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and Rivoceranib in small cell lung cancer (SCLC), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: progression-free survival and objective response rate. Started Feb 2020; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR1900028023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028023.